Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651Robert I. Haddad, Athanassios Argiris, Kevin J. Harrington et al.|Journal of Clinical Oncology|2022Cited by 159
Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.Robert L. Ferris, Yukihiro Nishiyama, Athanassios Argiris et al.|Journal of Clinical Oncology|2014Cited by 30